Even as Clinton Bashes Drugmakers, Insurers May Still Feel Heat
- The Democratic candidate has pushed cost control since 1990s
- In campaign, Clinton spreads the blame for health-care expense
Democratic presidential candidate Hillary Clinton speaks on Feb. 2, 2016, in Nashua, New Hampshire.
Photographer: Justin Sullivan/Getty ImagesThis article is for subscribers only.
“Price-gouging.” “Predatory.” “Outrageous.” Those are just a few of the barbs presidential candidates, including Hillary Clinton, have thrown the way of the pharmaceutical industry this campaign season.
That rhetoric helped sink drug and biotech stocks over the last six months and has overshadowed the candidates’ criticism of the rest of the health-care system, including insurers. Yet those businesses could be just as much at risk if the next president, whoever that may be, persists in calling out health-care companies on cost.